Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.46 |
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198528 | 1.00 | CYP1A2 (0.50) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL1934550 | 0.98 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL2257624 | 0.98 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Sulfuric Acid SCHEMBL1521031 | 0.92 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| Sulfuric Acid SCHEMBL1521033 | 0.92 | CYP1A2 (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL15405381 | 0.86 | LMNA (0.42) | CYP1A2FOLH1 | |
| SCHEMBL2984814 | 0.84 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL2984816 | 0.84 | CYP1A2 (0.48) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL14319857 | 0.84 | GABRP (0.43) | CYP1A2TET2KDM4AKDM4CKDM2A | |
| SCHEMBL1082587 | 0.83 | FFAR4 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321490-A | Auxiliary agent and preparation method thereof | 宿迁联盛科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| CN-105001108-B | The preparation method of the dimethyl glutamate derivatives of optical voidness 3,4 | 河北科技大学 | 2017-10-13 | — | — | CN | claimed |
| CN-105001108-A | Optical pure 3,4-dimethyl glutamic acid derivative preparation method | UNIV HEBEI SCIENCE & TECH | 2015-10-28 | — | — | CN | claimed |
| CN-101475565-A | Anti-hypertension compound, and preparation, pharmaceutical composition and use thereof | JIANMIN WANG (CN) | 2009-07-08 | — | — | CN | claimed |
| CN-101314600-A | Antineoplastic compound, medicament composition and use thereof | JIANMIN WANG (CN) | 2008-12-03 | — | — | CN | claimed |
| EP-0506207-B1 | Pharmaceutical vehicles for reducing transdermal flux | ACCESS PHARMA INC (US) | 1999-11-17 | — | — | EP | claimed |
| EP-0872248-A2 | Pharmaceutical vehicles for reducing transdermal flux | Access Pharmaceuticals, Inc. (US) | 1998-10-21 | — | — | EP | claimed |
| EP-0506207-A2 | Pharmaceutical vehicles for reducing transdermal flux | CHEMEX PHARMACEUTICALS, Inc. (US) | 1992-09-30 | — | — | EP | claimed |
| US-4895727-A | Using water soluble zinc compound | CHEMEX PHARMACEUTICALS, INC. (US) | 1990-01-23 | — | — | US | claimed |
| EP-0259133-A2 | Use of organic buffers to reduce dehydroascorbic acid interference in analytical methods | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1988-03-09 | — | — | EP | claimed |
| US-20250288531-A1 | AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4534525-A1 | AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| CN-116179017-B | Inkjet ink composition and recording method | 精工爱普生株式会社 | 2024-07-19 | — | — | CN | disclosed |
| WO-1983001725-A1 | MEDICAL PROCESS AND PREPARATION | JOHNSTON, FREDERICK, BERTRAM | 1983-05-26 | — | — | WO | disclosed |
| WO-1983001725-A1 | MEDICAL PROCESS AND PREPARATION | JOHNSTON, FREDERICK, BERTRAM | 1983-05-26 | — | — | WO | disclosed |
| US-4362745-A | Medical process and preparation | JOHNSTON FREDERICK B | 1982-12-07 | — | — | US | disclosed |
| US-4362745-A | Medical process and preparation | JOHNSTON FREDERICK B | 1982-12-07 | — | — | US | disclosed |
| EP-0049606-A1 | Detection method, use and diagnostic aid | Self, Colin Henry (GB) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CYP1A2 3894/4885TET2 1901/4885KDM4A 3286/4885 |
| US-20250288531-A1 | AMINO ACID-BASED CATIONIC LIPID CONTAINING UNSATURATED BONDS | SLC7A1, LNPEP, SLC1A5 | CYP1A2 3743/4885TET2 4761/4885KDM4A 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.